https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48434 75%. This corresponded to an overall reduction in seizure frequency from 32 to 7.2 seizures per month. Ninety-one percent of adverse events were mild or moderate, and none required drug withdrawal. Sixty-two percent were judged to be unrelated to CBDV. Thirty-one percent of adverse events were identified as possibly related, of which nearly all were mild, and the remainder were later assessed as RTT symptoms. Hypersomnolence and drooling were identified as related to CBDV. No serious adverse events reported were related to CBDV. No significant change was noted in EEG or non-epilepsy-related symptoms of RTT. Significance: A dose of 10 mg/kg/day of CBDV is safe and well tolerated in a pediatric RTT cohort and suggests improved seizure control in children with MECP2-related RTT.]]> Thu 16 Mar 2023 14:17:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44512 Fri 14 Oct 2022 09:11:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42761 Fri 02 Sep 2022 08:40:30 AEST ]]>